Sandoz has announced the launch of Pirfenidone tablets, the first AB-rated equivalent to Esbriet®, for the treatment of idiopathic pulmonary fibrosis.

The generic version is available in 2 dosage strengths: 267mg (in 270-count bottles) and 801mg (in 90-count bottles). 

“Sandoz is putting patients first by expanding access to generic pirfenidone for those living with this rare disease, who will benefit from a more affordable, yet equally effective treatment,” said Keren Haruvi, President, Sandoz Inc. “We developed this medicine in-house and continue to build our expertise and infrastructure to support our long-term commitment to grow our respiratory portfolio.”

The Company is providing a co-pay program for eligible patients.

Reference

Sandoz launches first generic pirfenidone in US for patients with idiopathic pulmonary fibrosis, growing its respiratory portfolio. News release. May 13, 2022. https://www.prnewswire.com/news-releases/sandoz-launches-first-generic-pirfenidone-in-us-for-patients-with-idiopathic-pulmonary-fibrosis-growing-its-respiratory-portfolio-301545367.html